Endobronchial Ultrasound Biopsy Market is expected to reach US$ 1.43 billion by 2034 from US$ 861.25 million in 2025, with a CAGR of 5.83% from 2026 to 2034. The endobronchial ultrasound biopsy market is expected to witness sustained growth during the forecast period, driven by increasing demand for minimally invasive diagnostics, advancements in bronchoscopy technologies, and growing focus on early lung disease detection.
Continuous technological advancements are driving innovation across the endobronchial ultrasound biopsy industry. Manufacturers are introducing bronchoscopes with enhanced flexibility, high-definition ultrasound imaging, improved needle guidance systems, and ergonomic designs that support greater procedural accuracy and physician efficiency. The integration of digital imaging platforms, navigation technologies, and artificial intelligence-assisted visualization is further improving lesion localization and biopsy precision. At the same time, increasing investments in healthcare infrastructure, specialized pulmonary departments, and physician training programs are expanding access to advanced bronchoscopy services.
In order to diagnose and assess the severity of respiratory conditions like lung and bronchus cancer, tuberculosis, and chronic obstructive pulmonary disease (COPD), endobronchial ultrasound biopsy is used to take tissue or fluid samples from the lungs and surrounding lymph nodes without the need for traditional surgery. For example, the American Lung Association's 2024 data show that 11.7 million Americans, or 4.6% of the adult population, were diagnosed with COPD in 2022. This results in a sizable patient population that would need to be diagnosed. In a similar vein, around one in fourteen (7.0%) persons 65 years of age and older have been diagnosed with COPD, according to the Australian Bureau of Statistics 2022 update. Thus, the market for endobronchial ultrasonography biopsies may be driven by the increasing incidence of respiratory conditions.
Furthermore, home air pollution is a major risk factor in low- and middle-income countries (LMICs), even though smoking is the primary cause of COPD, especially in high-income nations. This is particularly worrisome because smoking rates are rising in LMICs, which could lead to an explosion of COPD patients in the upcoming decades. The need for precise and early diagnosis techniques like EBUS is anticipated to increase in the near future as the prevalence of COPD increases worldwide, especially in LMICs. Over the course of the forecast period, the need for precise and minimally invasive diagnostic technologies like EBUS is expected to increase due to the general increase in respiratory disorders.
The rising incidence of respiratory illnesses, one of the main causes of death in the nation, is fueling the expansion of the endobronchial ultrasound biopsy market in the United States. The Centers for Disease Control and Prevention (CDC) anticipated that 4.3% of persons over the age of 18 had chronic bronchitis, emphysema, or COPD in 2023. Over the course of the projection period, it is anticipated that the demand for minimally invasive treatments like EBUS would increase as more patients seek early diagnosis and treatment.
A number of convergent factors, such as the introduction of a national low-dose CT (LDCT) lung cancer screening program aimed at high-risk individuals in July 2024 - a significant milestone in early cancer detection - are driving the market for endobronchial ultrasound (EBUS) biopsies in Germany. The program, which focuses on those with heavy smoking histories between the ages of 50 and 75, requires two radiologists to double-read and analyze every scan. It incorporates AI help. Referrals for EBUS operations for diagnostic confirmation will inevitably rise as a result. in specialized and academic institutions in Germany.
Endobronchial ultrasound biopsy Industry Overview
The endobronchial ultrasound (EBUS) biopsy industry has emerged as a vital component of modern pulmonary diagnostics by providing a minimally invasive approach for examining lung lesions and mediastinal lymph nodes. The procedure combines bronchoscopy with ultrasound imaging, enabling physicians to obtain real-time visualization of structures surrounding the airways while collecting tissue samples for pathological analysis. EBUS biopsy is widely used in the diagnosis and staging of lung cancer, evaluation of enlarged lymph nodes, and assessment of infectious and inflammatory pulmonary diseases. Compared with traditional surgical biopsy techniques, it offers several clinical advantages, including reduced procedural risk, shorter recovery time, lower healthcare costs, and improved patient comfort. As healthcare providers increasingly emphasize early diagnosis and precision medicine, EBUS biopsy has become a preferred diagnostic technique in hospitals, specialty respiratory centers, and cancer treatment facilities. Growing awareness among clinicians regarding minimally invasive procedures and the expanding use of multidisciplinary care for thoracic diseases continue to support market development.Continuous technological advancements are driving innovation across the endobronchial ultrasound biopsy industry. Manufacturers are introducing bronchoscopes with enhanced flexibility, high-definition ultrasound imaging, improved needle guidance systems, and ergonomic designs that support greater procedural accuracy and physician efficiency. The integration of digital imaging platforms, navigation technologies, and artificial intelligence-assisted visualization is further improving lesion localization and biopsy precision. At the same time, increasing investments in healthcare infrastructure, specialized pulmonary departments, and physician training programs are expanding access to advanced bronchoscopy services.
In order to diagnose and assess the severity of respiratory conditions like lung and bronchus cancer, tuberculosis, and chronic obstructive pulmonary disease (COPD), endobronchial ultrasound biopsy is used to take tissue or fluid samples from the lungs and surrounding lymph nodes without the need for traditional surgery. For example, the American Lung Association's 2024 data show that 11.7 million Americans, or 4.6% of the adult population, were diagnosed with COPD in 2022. This results in a sizable patient population that would need to be diagnosed. In a similar vein, around one in fourteen (7.0%) persons 65 years of age and older have been diagnosed with COPD, according to the Australian Bureau of Statistics 2022 update. Thus, the market for endobronchial ultrasonography biopsies may be driven by the increasing incidence of respiratory conditions.
Furthermore, home air pollution is a major risk factor in low- and middle-income countries (LMICs), even though smoking is the primary cause of COPD, especially in high-income nations. This is particularly worrisome because smoking rates are rising in LMICs, which could lead to an explosion of COPD patients in the upcoming decades. The need for precise and early diagnosis techniques like EBUS is anticipated to increase in the near future as the prevalence of COPD increases worldwide, especially in LMICs. Over the course of the forecast period, the need for precise and minimally invasive diagnostic technologies like EBUS is expected to increase due to the general increase in respiratory disorders.
Growth Drivers for the Endobronchial ultrasound biopsy Market
Increasing Preference for Minimally Invasive Diagnostic Procedures
The growing shift toward minimally invasive medical procedures is a major driver of the endobronchial ultrasound biopsy market. Physicians increasingly prefer EBUS because it enables accurate tissue sampling without requiring open surgical intervention. The procedure minimizes patient discomfort, reduces complications, shortens recovery periods, and lowers hospitalization requirements compared to conventional surgical biopsies. These advantages improve both patient experience and healthcare efficiency while supporting faster clinical decision-making. Hospitals and respiratory specialists are expanding the use of EBUS for diagnosing pulmonary diseases, staging lung cancer, and evaluating mediastinal lymph nodes. As healthcare systems continue emphasizing minimally invasive treatment pathways, demand for endobronchial ultrasound biopsy systems is expected to increase significantly across global healthcare facilities.Rising Focus on Early Lung Cancer Diagnosis
Early diagnosis plays a critical role in improving outcomes for patients with lung cancer, making advanced biopsy technologies increasingly valuable. Endobronchial ultrasound biopsy allows clinicians to obtain high-quality tissue samples from difficult-to-access lymph nodes and lung lesions while supporting accurate disease staging. Earlier identification of malignant conditions enables physicians to initiate appropriate treatment strategies and improve long-term patient prognosis. Expanding awareness of lung cancer screening and precision oncology has increased the utilization of EBUS procedures in comprehensive cancer care. Healthcare providers continue integrating advanced diagnostic technologies into multidisciplinary oncology programs to improve diagnostic confidence and personalized treatment planning, thereby supporting continued market growth.Technological Advancements in Bronchoscopy and Imaging
Continuous innovation in bronchoscopy equipment and ultrasound imaging technologies is strengthening the endobronchial ultrasound biopsy market. Modern EBUS systems provide enhanced image resolution, superior needle guidance, improved visualization of surrounding anatomy, and greater procedural accuracy. Artificial intelligence-assisted imaging, navigation technologies, and digital workflow solutions are helping clinicians perform more efficient and reliable diagnostic procedures. Manufacturers are also developing lightweight bronchoscopes and advanced biopsy accessories that improve physician maneuverability while enhancing patient safety. These technological improvements increase procedural success rates and expand the clinical applications of endobronchial ultrasound biopsy across respiratory medicine. Ongoing research and product innovation are expected to drive further market expansion.Challenges in the Endobronchial ultrasound biopsy Market
High Equipment Costs and Infrastructure Requirements
The adoption of endobronchial ultrasound biopsy systems requires substantial investment in specialized medical equipment, imaging technologies, and healthcare infrastructure. Hospitals must acquire advanced bronchoscopy platforms, ultrasound processors, biopsy instruments, and supporting accessories while maintaining regular equipment servicing and upgrades. These financial requirements may limit adoption among smaller healthcare facilities and institutions with constrained budgets. Establishing dedicated bronchoscopy suites also requires significant infrastructure planning and operational investment. Cost considerations can slow technology implementation, particularly in developing healthcare markets where financial resources remain limited. Expanding affordability and improving access to advanced pulmonary diagnostic technologies remain important priorities for broader market adoption.Requirement for Specialized Clinical Expertise
Successful performance of endobronchial ultrasound biopsy procedures depends on highly trained pulmonologists, thoracic specialists, and bronchoscopy teams with specialized procedural expertise. Accurate interpretation of ultrasound images, proper needle positioning, and effective tissue sampling require extensive clinical experience and ongoing professional training. Limited availability of experienced specialists may reduce procedural capacity in certain healthcare settings. Additionally, healthcare organizations must invest in continuous education programs to ensure clinicians remain proficient with evolving technologies and procedural techniques. Standardizing training programs and expanding specialist availability are essential for maximizing the clinical effectiveness and accessibility of endobronchial ultrasound biopsy services worldwide.United States Endobronchial ultrasound biopsy Market
The United States represents a leading market for endobronchial ultrasound biopsy, supported by advanced pulmonary care infrastructure, widespread adoption of minimally invasive diagnostics, and strong emphasis on early lung cancer detection. Hospitals and specialized respiratory centers increasingly utilize EBUS technology for accurate diagnosis and staging of thoracic diseases. Continuous investment in medical innovation, combined with strong collaboration between healthcare providers and medical device manufacturers, has accelerated the adoption of sophisticated bronchoscopy platforms. Growing integration of precision oncology and multidisciplinary cancer care further supports the use of image-guided biopsy procedures. As healthcare providers continue prioritizing accurate diagnosis with reduced patient risk, endobronchial ultrasound biopsy remains an essential component of respiratory medicine across the United States.The rising incidence of respiratory illnesses, one of the main causes of death in the nation, is fueling the expansion of the endobronchial ultrasound biopsy market in the United States. The Centers for Disease Control and Prevention (CDC) anticipated that 4.3% of persons over the age of 18 had chronic bronchitis, emphysema, or COPD in 2023. Over the course of the projection period, it is anticipated that the demand for minimally invasive treatments like EBUS would increase as more patients seek early diagnosis and treatment.
Germany Endobronchial ultrasound biopsy Market
Germany has established a strong endobronchial ultrasound biopsy market through its advanced healthcare infrastructure, highly specialized pulmonary medicine services, and commitment to medical technology innovation. Hospitals and university medical centers increasingly rely on EBUS procedures for diagnosing lung diseases and evaluating mediastinal abnormalities with greater precision. The country's focus on minimally invasive clinical practices and evidence-based healthcare supports widespread adoption of modern bronchoscopy systems. Continuous collaboration between medical technology companies, research institutions, and healthcare providers contributes to ongoing improvements in diagnostic capabilities. Growing investment in specialized respiratory care and early cancer diagnosis continues to strengthen the demand for endobronchial ultrasound biopsy solutions throughout Germany.A number of convergent factors, such as the introduction of a national low-dose CT (LDCT) lung cancer screening program aimed at high-risk individuals in July 2024 - a significant milestone in early cancer detection - are driving the market for endobronchial ultrasound (EBUS) biopsies in Germany. The program, which focuses on those with heavy smoking histories between the ages of 50 and 75, requires two radiologists to double-read and analyze every scan. It incorporates AI help. Referrals for EBUS operations for diagnostic confirmation will inevitably rise as a result. in specialized and academic institutions in Germany.
China Endobronchial ultrasound biopsy Market
China's endobronchial ultrasound biopsy market is expanding rapidly as healthcare providers enhance respiratory diagnostic capabilities and strengthen oncology services. Hospitals are increasingly adopting advanced bronchoscopy technologies to improve diagnostic accuracy while reducing reliance on invasive surgical procedures. Government initiatives supporting healthcare modernization and expansion of specialized medical services have accelerated the implementation of sophisticated pulmonary diagnostic equipment. Domestic manufacturers and international medical technology companies continue introducing innovative bronchoscopy solutions to meet growing clinical demand. Rising awareness regarding early lung disease detection and precision medicine is further encouraging adoption. As healthcare infrastructure continues to evolve, endobronchial ultrasound biopsy is expected to play an increasingly important role in China's respiratory healthcare system.United Arab Emirates Endobronchial ultrasound biopsy Market
The UAE is steadily advancing its endobronchial ultrasound biopsy market through continued investment in specialized respiratory care, modern hospital infrastructure, and advanced diagnostic technologies. Healthcare providers are increasingly utilizing EBUS procedures to support early diagnosis of lung cancer, infectious diseases, and mediastinal disorders while minimizing patient discomfort. Expansion of specialized pulmonary centers and growing adoption of minimally invasive diagnostic approaches are strengthening demand for advanced bronchoscopy systems. Government initiatives promoting healthcare excellence and medical innovation continue to support technology adoption across public and private healthcare institutions. Collaboration with international healthcare organizations and medical device manufacturers is further enhancing clinical capabilities. As respiratory medicine continues to evolve in the UAE, endobronchial ultrasound biopsy is expected to become an increasingly valuable diagnostic tool.Recent Developments in Endobronchial ultrasound biopsy Market
- To improve lung cancer diagnosis and staging, Olympus Corporation announced in September 2025 that its newest EBUS bronchoscope, the BF-UCP190F, would be available in major APAC and EMEA markets. Physicians can access deeper lung regions and carry out more accurate real-time tissue sample because to the device's increased mobility, wider upward angulation, and thinner 5.9 mm outer diameter.
- Through its recently formed local company, Olympus Latin America is now able to directly sell, distribute, and service its entire medical technology range in-market after acquiring the distribution business from Sur Medical SpA in Chile in January 2025.
Endobronchial Ultrasound Biopsy Market Segmentation
Product
- EBUS Scopes
- EBUS Needles
- Ultrasound Processors and Imaging Systems
- Accessories
Application
- Cancer Diagnostic
- Infection Diagnostic
- Others
End Use
- Hospitals
- Ambulatory Surgical Centers (ASCs)
- Specialty Clinics
Countries
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Turkey
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Malaysia
- Indonesia
- New Zealand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
All the Key players have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments
- SWOT Analysis
- Revenue Analysis
Key Players Analysis
- GE Healthcare
- Siemens Healthcare Private Limited
- Koninklijke Philips N.V.
- Boston Scientific Corporation
- Olympus Corporation
- Cook Group Incorporated
- FUJIFILM Holdings Corporation
- Medi-Globe Technologies GmbH
Table of Contents
1. Introduction3. Executive Summary13. Merger and Acquisition
2. Research Methodology
4. Market Dynamics
5. Global Endobronchial Ultrasound Biopsy Market
6. Global Endobronchial Ultrasound Biopsy Market Share Analysis
7. Product - Historical and Current Market Trends & Forecast
8. Application - Historical and Current Market Trends & Forecast
9. End Use - Historical and Current Market Trends & Forecast
10. Countries - Historical and Current Market Trends & Forecast
11. Porter’s Five Forces Analysis
12. SWOT Analysis
14. Key Players Analysis
Companies Mentioned
- GE Healthcare
- Siemens Healthcare Private Limited
- Koninklijke Philips N.V.
- Boston Scientific Corporation
- Olympus Corporation
- Cook Group Incorporated
- FUJIFILM Holdings Corporation
- Medi-Globe Technologies GmbH
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | June 2026 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 861.25 Million |
| Forecasted Market Value ( USD | $ 1430 Million |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
